




Clinical study of Biomefix

Short version

Body & Future Laboratories / 21 November 2024





RESEARCH TEAM

Product Developer and Scientific Coordination: Ing. Ján Durec PhD., McCarter a.s Bajkalská 25, Bratislava

Research team: doc. Ing. Radoslav Židek, PhD., SPU in Nitra.

Expert no. 914837, Field: 310000, Branch: 310200 Examination of Food Products.

Doc. MUDr. Adela Penesová PhD., Biomedical Centre (BMC) of the Slovak Academy of Sciences, Bratislava

MUDr. Miroslav Vlček PhD., BMC SAV Bratislava

Mgr. Jitka Novotná, Ph.D., Bio Verdor Group MDx Brno

Expert consultants:

Mgr. Eva Pindurová, Ph.D. FORLAB Brno

Doc. Mgr. Martina Lengerová PhD., Centre for Molecular Biology and Genetics, University Hospital Brno, Brno,
Czech Republic,

MUDr. Markéta Hanslianová, University Hospital Brno



The study involved 50 healthy participants, comprising 50% women and 50% men, with an age range of 25 to 65 years. The participants were primarily researchers from various fields and positions, with some exhibiting mild signs of obesity.

The intervention lasted 30 days, during which participants took 60 ml of Biomefix each morning on an empty stomach. This product is registered as a dietary supplement.

The clinical study received approval from the Ethics Committee in Bratislava.

Biological material collected:

- blood and stool

The analysis was carried out by accredited laboratories, and all materials remained within the EU.

Results of the study:

BODY PARAMETERS

The study observed a decrease in:

- BMI (body mass index)
- Waist circumference (reduction of 1cm)
- Body weight

BIOCHEMICAL PARAMETERS

The analysis revealed a decrease in the following blood parameter values:

- Glucose

- Uric acid
- HDL cholesterol fraction
- CRP (C-reactive protein)
- Protein level

These findings suggest that taking Biomefix improves the overall metabolism of sugars, fats, and proteins.

IMMUNITY:

- Interleukin levels were maintained
- C-reactive protein values decreased

CHANGES IN THE MICROBIOME

Taking probiotic products promotes a balance between health-promoting bacteria in the gut and harmful, pathogenic microorganisms.

The study demonstrated that the production of short-chain fatty acids (SCFAs) serves as an energy source for intestinal cells.

Shifting the balance in favor of beneficial bacteria positively influenced:

- Ph levels
- Production of antimicrobial substances
- Maintenance of microbiome balance


The metabolites of probiotics and beneficial bacteria help reduce inflammatory processes and support immune system balance. An increase in probiotic bacteria can enhance microbiota diversity by limiting the space and resources available to non-beneficial microorganisms in the body.

During the study, participants reported improved digestion. In future research, we plan to focus on testing Biomefix for specific gastrointestinal diagnoses, such as IBS and Crohn's disease.

Please consult your treating physician before using this product.

ANNEX NO.1

Vzorky 1 - 25



Vzorky 26 - 50

